Ventria Bioscience acquires Meristem Therapeutics' recombinant lactoferrin IP
Ventria Bioscience is acquiring exclusive ownership rights to intellectual property relating to Meristem Therapeutics' recombinant human lactoferrin.
Ventria Bioscience is to acquire intellectual property relating to recombinant lactoferrin developed by French biotechnology company Meristem Therapeutics.
Under the terms of the agreement, Ventria Bioscience will obtain exclusive royalty-free ownership rights for specific patents in the US, France and Canada in exchange for a one-off payment.
The agreement includes patents relating to recombinant human lactoferrin, which is the active ingredient in Ventria Bioscience's lead drug candidate VEN100.
VEN100 is currently being developed as a preventive treatment for antibiotic-associated diarrhoea in high-risk adults.
Scott Deeter, president and chief executive officer of Ventria Bioscience, said: "The patents acquired today cover important components of our product pipeline.
"The decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin."
Ventria Bioscience has solved the problem of producing commercial-scale yields of recombinant human lactoferrin using its proprietary ExpressTec technology platform.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance